MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$20.7M |
| 2 |
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$11.4M |
| 3 |
Xeris Biopharma Holdings
XERS
|
+$10.1M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$7.94M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$7.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
+$28.3M |
| 2 |
Inhibrx, Inc. Common Stock
INBX
|
+$22.5M |
| 3 |
uniQure
QURE
|
+$7.01M |
| 4 |
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
|
+$5.06M |
| 5 |
Arcutis Biotherapeutics
ARQT
|
+$2.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$728M
| $82.3M | 16.57% |
7,648,268
| – | – |
2021 Q1
9 quarters
|
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $47.8M | 9.62% |
1,214,662
+168,971
| +16% | +$5.96M |
2022 Q3
3 quarters
|
|
|
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $38.6M | 7.76% |
1,003,406
+805,600
| +407% | +$20.7M |
2022 Q4
2 quarters
|
|
4
Geron
GERN
$638M
| $29.5M | 5.94% |
9,191,290
+789,725
| +9% | +$2.25M |
2021 Q3
7 quarters
|
|
|
RETA
5
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $23.9M | 4.81% |
234,478
+57,604
| +33% | +$5.45M |
2022 Q1
5 quarters
|
|
6
DELISTED
iTeos Therapeutics
ITOS
| $23.1M | 4.65% |
1,745,943
| – | – |
2020 Q3
11 quarters
|
|
7
Intellia Therapeutics
NTLA
$1.59B
| $22.2M | 4.47% |
544,639
-27,820
| -5% | -$1.13M |
2021 Q3
7 quarters
|
|
8
Iovance Biotherapeutics
IOVA
$3.72B
| $20.8M | 4.18% |
2,950,118
+335,141
| +13% | +$2.4M |
2022 Q2
4 quarters
|
|
9
DELISTED
Repare Therapeutics
RPTX
| $17.3M | 3.49% |
1,639,849
| – | – |
2020 Q2
12 quarters
|
|
10
Relay Therapeutics
RLAY
$4.11B
| $17M | 3.43% |
1,354,368
+128,734
| +11% | +$1.6M |
2023 Q1
1 quarter
|
|
11
DELISTED
Verve Therapeutics
VERV
| $16.1M | 3.24% |
857,940
+54,439
| +7% | +$907K |
2022 Q3
3 quarters
|
|
|
12
MoonLake Immunotherapeutics
MLTX
$981M
| $15.1M | 3.03% |
+295,111
| New | +$7.94M |
2023 Q2
0 quarters
|
|
13
Regenxbio
RGNX
$504M
| $13.1M | 2.64% |
656,718
+39,047
| +6% | +$752K |
2022 Q3
3 quarters
|
|
|
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $11.6M | 2.33% |
+53,399
| New | +$11.4M |
2023 Q2
0 quarters
|
|
15
Insmed
INSM
$25.1B
| $11.2M | 2.25% |
529,743
+130,551
| +33% | +$2.48M |
2022 Q4
2 quarters
|
|
|
16
Xeris Biopharma Holdings
XERS
$2.78B
| $10.4M | 2.1% |
+3,974,999
| New | +$10.1M |
2023 Q2
0 quarters
|
|
17
Madrigal Pharmaceuticals
MDGL
$9.28B
| $8.78M | 1.77% |
38,011
+1,973
| +5% | +$534K |
2022 Q2
4 quarters
|
|
18
DELISTED
Crinetics Pharmaceuticals
CRNX
| $8.63M | 1.74% |
479,053
+118,661
| +33% | +$2.37M |
2021 Q3
7 quarters
|
|
19
Travere Therapeutics
TVTX
$4.76B
| $8.49M | 1.71% |
552,846
+239,204
| +76% | +$4.35M |
2021 Q3
7 quarters
|
|
20
Revolution Medicines
RVMD
$41.6B
| $7.31M | 1.47% |
273,408
+26,386
| +11% | +$647K |
2021 Q3
7 quarters
|
|
21
Werewolf Therapeutics
HOWL
$49.1M
| $7.28M | 1.47% |
2,388,011
| – | – |
2021 Q2
8 quarters
|
|
|
22
DELISTED
KalVista Pharmaceuticals
KALV
| $6.85M | 1.38% |
+761,538
| New | +$7.02M |
2023 Q2
0 quarters
|
|
23
Axsome Therapeutics
AXSM
$6.96B
| $6.73M | 1.35% |
93,586
+23,184
| +33% | +$1.71M |
2022 Q4
2 quarters
|
|
24
DELISTED
Amicus Therapeutics
FOLD
| $6.48M | 1.31% |
516,139
+127,847
| +33% | +$1.52M |
2021 Q3
7 quarters
|
|
|
AVDL
25
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.34M | 1.28% |
+384,990
| New | +$5M |
2023 Q2
0 quarters
|
|
Similar funds
MPM BioImpact's Q2 2023 Portfolio in Review
As of Q2 2023, MPM BioImpact held 41 positions worth $497M, up 29% from $385M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
MPM BioImpact deployed $51.3M of net new capital in Q2 2023, opening 10 new positions and adding to 17 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 53,399 shares worth $11.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Intellia Therapeutics, an estimated $1.13M trimmed.
- MPM BioImpact's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 53,399 shares worth $11.6M.
- MPM BioImpact added most to Chinook Therapeutics, Inc. Common Stock in Q2 2023, an estimated $20.7M increase.
- MPM BioImpact's biggest Q2 2023 reduction was Intellia Therapeutics, cutting an estimated $1.13M.
- MPM BioImpact fully exited Provention Bio, Inc. Common Stock in Q2 2023, selling an estimated $28.3M.
- MPM BioImpact's ten largest holdings make up 65% of its $497M portfolio in Q2 2023.
- MPM BioImpact opened 10 new positions and closed 7 in Q2 2023.
- MPM BioImpact's portfolio value rose 29% quarter-over-quarter to $497M.
Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.